



FACSIMILE



NOTICE OF CONFIDENTIALITY

This transmission is intended only for the use of the Addressee and may contain information that is: 1. Subject to attorney/client privilege; 2. Attorney work product; or 3. Confidential. If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copying of the information contained in this facsimile is strictly unauthorized and prohibited. If you have received this facsimile in error, please notify us immediately by collect telephone to the sender named below.

DATE: January 17, 2003

TO: Examiner Delacroix Muirhei

FAX RECEIVED

NUMBER OF PAGES: 14 (including cover)

JAN 17 2003

FAX NO: 703-308-4242

GROUP 1600

FROM: Lisa A. Samuels
PFIZER INC.
PATENT DEPARTMENT
EASTERN POINT ROAD
GROTON, CT 06340
(860) 686-0349

RE: U.S. Serial No. 09/308,955
Our reference: PC9808A

OFFICIAL

FACSIMILE NO.: (860) 441-5221

FACSIMILE UNIT: PITNEY BOWES 2050

S/N 09/308955
Attorney Docket No. PC9808AIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Lundy et al. Examiner: Delacroix
Serial No.: 09/308955 Group Art Unit: 1614
Filed: May 27, 1999 Docket No.: PC9808A
Title: COX-2 SELECTIVE CARPROFEN FOR TREATING PAIN AND
INFLAMMATION IN DOGS

CERTIFICATE OF TRANSMISSION: The undersigned hereby certifies that this correspondence, and all papers filed herewith, is being filed via facsimile transmission to fax phone number (703) 308-4242 on January 17, 2003.

By: Lisa A. Samuels
Lisa A. Samuels, Reg. No. 43,080

RESPONSE TO OFFICE ACTION

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Office Action mailed November 4, 2002, please amend this application as indicated herein.

Clean Form of Amended Claims

Please cancel claims ~~5~~, 8-14, 24-25 and ~~26-33~~ without prejudice and amend claims 4, 15, 18 and 21 as indicated below (marked-up forms are included herewith as Exhibit A):

4. (Three Times Amended) A method of treating or preventing inflammatory processes and diseases as in Claim 1 further comprising wherein said inhibitory compound is used in combination with one or more other therapeutically active agents under the following conditions:

A. where a joint has become seriously inflamed as well as infected at the same time by bacteria, fungi, protozoa, and/or virus, said inhibitory compound is administered in combination with one or more antibiotic, antifungal, antiprotozoal, and/or antiviral therapeutic agents;